Alnylam Picks PCSK9 Cholesterol Drug As Newest Candidate, Shelving apoB

/Home/Biologics Delivery - Protein Synthesis/RNA - Protein Synthesis/RNAi - Protein Synthesis

Alnylam Picks PCSK9 Cholesterol Drug As Newest Candidate, Shelving apoB
By Doug Macron
December 7, 2006
RNAi News
The company also said it expects that one of the two INDs it plans to file next year will be for a PCSK9-targeting therapeutic, which would be Alnylam?s first systemically delivered RNAi drug candidate.
Paid subscription is required to view article.